Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Recent Developments and the Use of "Real-Time Liquid Biopsy" with Circulating Tumour Cells in Ovarian Cancer

Wilson Steve*

An abnormal mass of tissue that forms once cells grow and divide quite ought to they ought to they must} or don't die once they should. Tumors could also be benign (not cancer) or malignant (cancer). Benign tumors could grow however don't unfold into, or invade, near tissues or alternative components of the body. Malignant tumors will unfold into, or invade, near tissues. They will conjointly unfold to alternative components of the body through the blood and liquid body substance systems conjointly known as tumor. Even with the most recent advances in technology, the treatment of gonad cancer remains an enormous challenge as a result of it's usually diagnosed at advanced stage, is at risk of early relapse in spite of aggressive treatment and has an especially poor prognosis. Current growth cells (CTCs) are often used as a non-invasive “real-time liquid biopsy”, that has shown the worth of diagnosing, assessment of prognosis and chemo resistance, and detection of tiny residual tumors on gonad cancer. This critique provides a summary on recent analysis on CTCs in gonad cancer, with special specialize in the clinical application of CTC tests.

Keywords: Circulating tumor cells; Liquid biopsy; Microfluidics Ovarian cancer; Cancer research; Tumor; Gonad cancer

Published Date: 2022-10-27; Received Date: 2022-09-29